Identification

Name
Panobinostat
Accession Number
DB06603
Type
Small Molecule
Groups
Approved, Investigational
Description

Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is marketed by Novartis under the brand name Farydak. Panobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market.

Structure
Thumb
Synonyms
  • (2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide
  • panobinostat
External IDs
LBH589
Product Ingredients
IngredientUNIICASInChI Key
Panobinostat hydrateD07V79Q44TNot AvailableYUKVPQZUSANPNW-ASTDGNLGSA-N
Panobinostat lactateHN0T99OO4V960055-56-5XVDWNSFFSMWXJJ-ASTDGNLGSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
FarydakCapsule20 mgOralNovartis Europharm Limited2015-08-28Not applicableEu
FarydakCapsule10 mgOralNovartis Europharm Limited2015-08-28Not applicableEu
FarydakCapsule15 mgOralNovartis Europharm Limited2015-08-28Not applicableEu
FarydakCapsule10 mgOralNovartis Europharm Limited2015-08-28Not applicableEu
FarydakCapsule15 mg/1OralNovartis2015-02-23Not applicableUs
FarydakCapsule20 mgOralNovartis Europharm Limited2015-08-28Not applicableEu
FarydakCapsule15 mgOralNovartis Europharm Limited2015-08-28Not applicableEu
FarydakCapsule10 mg/1OralNovartis2015-02-23Not applicableUs
FarydakCapsule10 mgOralNovartis Europharm Limited2015-08-28Not applicableEu
FarydakCapsule20 mgOralNovartis Europharm Limited2015-08-28Not applicableEu
Categories
UNII
9647FM7Y3Z
CAS number
404950-80-7
Weight
Average: 349.434
Monoisotopic: 349.179026993
Chemical Formula
C21H23N3O2
InChI Key
FPOHNWQLNRZRFC-ZHACJKMWSA-N
InChI
InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+
IUPAC Name
N-hydroxy(2E)-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enimidic acid
SMILES
[H]\C(=C(\[H])C1=CC=C(CNCCC2=C(C)NC3=CC=CC=C23)C=C1)C(O)=NO

Pharmacology

Indication

Panobinostat is indicated in the treatment of multiple myeloma in combination with dexamethasone and bortezomib in patients who have received 2 previous treatment regimens including bortezomib and an immunomodulatory agent. This indication is approved by accelerated approval based on progression free survival as of February 23, 2015.

Structured Indications
Pharmacodynamics
Not Available
Mechanism of action

Panobinostat is a deacetylase (DAC) inhibitor. DACs, also known as histone DACs (HDAC), are responsible for regulating the acetylation of about 1750 proteins in the body; their functions are involved in many biological processes including DNA replication and repair, chromatin remodelling, transcription of genes, progression of the cell-cycle, protein degradation and cytoskeletal reorganization. In multiple myeloma, there is an overexpression of DAC proteins. Panobinostat inhibits class I (HDACs 1, 2, 3, 8), class II (HDACs 4, 5, 6, 7, 9, 10) and class IV (HDAC 11) proteins. Panobinostat's antitumor activity is believed to be attributed to epigenetic modulation of gene expression and inhibition of protein metabolism. Panobinostat also exhibits cytotoxic synergy with bortezomib, a proteasome inhibitor concurrently used in treatment of multiple myeloma.

TargetActionsOrganism
AHistone deacetylase
inhibitor
Human
Absorption

After a 20 mg dose, panobinostat was quickly absorbed with a time to maximum absorption of 2 hours.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Panobinostat was extensively metabolized to 77 metabolites. Unchanged panobinostat recovered in urine and feces was 2% and 3%, respectively. Primary metabolic pathways of panobinostat are reduction, hydrolysis, oxidation, and glucuronidation processes. CYP and non-CYP enzymes were found to play significant role in metabolism, CYP2D6 and CYP2C19 playing minor roles.

Route of elimination
Not Available
Half life

30 hours

Clearance
Not Available
Toxicity

Farydak carries a Boxed Warning alerting patients and health care professionals that severe diarrhea and severe and fatal cardiac events, arrhythmias and electrocardiogram (ECG) changes have occurred in patients receiving Farydak. Because of these risks, Farydak is being approved with a Risk Evaluation and Mitigation Strategy (REMS) consisting of a communication plan to inform health care professionals of these risks and how to minimize them.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
4-MethoxyamphetamineThe serum concentration of 4-Methoxyamphetamine can be increased when it is combined with Panobinostat.Experimental, Illicit
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Panobinostat.Approved
AcetylcholineThe serum concentration of Acetylcholine can be increased when it is combined with Panobinostat.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Panobinostat.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Panobinostat.Experimental
AjmalineThe serum concentration of Ajmaline can be increased when it is combined with Panobinostat.Approved, Investigational
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Panobinostat.Approved, Investigational
AlogliptinThe serum concentration of Alogliptin can be increased when it is combined with Panobinostat.Approved
AlprenololThe serum concentration of Alprenolol can be increased when it is combined with Panobinostat.Approved, Withdrawn
AmantadineAmantadine may increase the QTc-prolonging activities of Panobinostat.Approved
AminophenazoneThe serum concentration of Aminophenazone can be increased when it is combined with Panobinostat.Approved, Withdrawn
AmiodaroneThe serum concentration of Panobinostat can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Panobinostat.Approved
AmoxapineThe serum concentration of Amoxapine can be increased when it is combined with Panobinostat.Approved
AmphetamineThe serum concentration of Amphetamine can be increased when it is combined with Panobinostat.Approved, Illicit
AmprenavirThe serum concentration of Amprenavir can be increased when it is combined with Panobinostat.Approved
AmsacrineThe serum concentration of Amsacrine can be increased when it is combined with Panobinostat.Approved
AnagrelidePanobinostat may increase the QTc-prolonging activities of Anagrelide.Approved
AntipyrineThe serum concentration of Antipyrine can be increased when it is combined with Panobinostat.Approved
ApomorphineApomorphine may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
AprepitantThe serum concentration of Panobinostat can be increased when it is combined with Aprepitant.Approved, Investigational
AprindineThe serum concentration of Aprindine can be increased when it is combined with Panobinostat.Approved
ArformoterolThe serum concentration of Arformoterol can be increased when it is combined with Panobinostat.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Panobinostat.Approved, Investigational
Arsenic trioxidePanobinostat may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherThe serum concentration of Artemether can be increased when it is combined with Panobinostat.Approved
AsenapinePanobinostat may increase the QTc-prolonging activities of Asenapine.Approved
AstemizoleThe serum concentration of Astemizole can be increased when it is combined with Panobinostat.Approved, Withdrawn
AtazanavirThe serum concentration of Panobinostat can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe serum concentration of Atomoxetine can be increased when it is combined with Panobinostat.Approved
AzelastineThe serum concentration of Azelastine can be increased when it is combined with Panobinostat.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Panobinostat.Approved
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Panobinostat.Investigational
BedaquilinePanobinostat may increase the QTc-prolonging activities of Bedaquiline.Approved
BenzatropineThe serum concentration of Benzatropine can be increased when it is combined with Panobinostat.Approved
Benzyl alcoholThe serum concentration of Benzyl alcohol can be increased when it is combined with Panobinostat.Approved
BepridilThe serum concentration of Bepridil can be increased when it is combined with Panobinostat.Approved, Withdrawn
BetaxololThe serum concentration of Betaxolol can be increased when it is combined with Panobinostat.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Panobinostat.Approved, Investigational
BisoprololThe serum concentration of Bisoprolol can be increased when it is combined with Panobinostat.Approved
BoceprevirThe serum concentration of Panobinostat can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe serum concentration of Bortezomib can be increased when it is combined with Panobinostat.Approved, Investigational
BosentanThe serum concentration of Panobinostat can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Panobinostat.Approved
BrompheniramineThe serum concentration of Brompheniramine can be increased when it is combined with Panobinostat.Approved
BufuralolThe serum concentration of Bufuralol can be increased when it is combined with Panobinostat.Experimental, Investigational
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Panobinostat.Approved, Investigational
BuprenorphineThe serum concentration of Buprenorphine can be increased when it is combined with Panobinostat.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Bupropion can be increased when it is combined with Panobinostat.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Panobinostat.Approved
BuspironeThe serum concentration of Buspirone can be increased when it is combined with Panobinostat.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Panobinostat.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Panobinostat.Approved
CaptoprilThe serum concentration of Captopril can be increased when it is combined with Panobinostat.Approved
CarbamazepineThe serum concentration of Panobinostat can be decreased when it is combined with Carbamazepine.Approved, Investigational
CariprazineThe serum concentration of Cariprazine can be increased when it is combined with Panobinostat.Approved
CarteololThe serum concentration of Carteolol can be increased when it is combined with Panobinostat.Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Panobinostat.Approved, Investigational
CephalexinThe serum concentration of Cephalexin can be increased when it is combined with Panobinostat.Approved, Vet Approved
CeritinibThe serum concentration of Panobinostat can be increased when it is combined with Ceritinib.Approved
CevimelineThe serum concentration of Cevimeline can be increased when it is combined with Panobinostat.Approved
ChlordiazepoxideThe serum concentration of Chlordiazepoxide can be increased when it is combined with Panobinostat.Approved, Illicit
ChloroquineThe serum concentration of Chloroquine can be increased when it is combined with Panobinostat.Approved, Vet Approved
ChlorphenamineThe serum concentration of Chlorphenamine can be increased when it is combined with Panobinostat.Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Panobinostat.Approved, Vet Approved
ChlorzoxazoneThe serum concentration of Chlorzoxazone can be increased when it is combined with Panobinostat.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Panobinostat.Approved
CinnarizineThe serum concentration of Cinnarizine can be increased when it is combined with Panobinostat.Approved, Investigational
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
CisapridePanobinostat may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Panobinostat.Approved
ClarithromycinThe serum concentration of Panobinostat can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Panobinostat can be decreased when combined with Clemastine.Approved
ClevidipineThe serum concentration of Clevidipine can be increased when it is combined with Panobinostat.Approved
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Panobinostat.Approved, Vet Approved
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Panobinostat.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Panobinostat.Approved
ClotrimazoleThe metabolism of Panobinostat can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Panobinostat.Approved
CobicistatThe serum concentration of Panobinostat can be increased when it is combined with Cobicistat.Approved
CodeineThe serum concentration of Codeine can be increased when it is combined with Panobinostat.Approved, Illicit
ConivaptanThe serum concentration of Panobinostat can be increased when it is combined with Conivaptan.Approved, Investigational
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Panobinostat.Approved
CrizotinibPanobinostat may increase the QTc-prolonging activities of Crizotinib.Approved
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Panobinostat.Approved
CyclophosphamideThe serum concentration of Cyclophosphamide can be increased when it is combined with Panobinostat.Approved, Investigational
CyclosporineThe metabolism of Panobinostat can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Panobinostat.Experimental
DabrafenibThe serum concentration of Panobinostat can be decreased when it is combined with Dabrafenib.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Panobinostat.Approved
DarifenacinThe serum concentration of Darifenacin can be increased when it is combined with Panobinostat.Approved, Investigational
DarunavirThe serum concentration of Panobinostat can be increased when it is combined with Darunavir.Approved
DasabuvirThe serum concentration of Dasabuvir can be increased when it is combined with Panobinostat.Approved
DasatinibThe serum concentration of Panobinostat can be increased when it is combined with Dasatinib.Approved, Investigational
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Panobinostat.Approved, Investigational
DeferasiroxThe serum concentration of Panobinostat can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Panobinostat.Approved
DelavirdineThe serum concentration of Delavirdine can be increased when it is combined with Panobinostat.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Panobinostat.Approved
DesfluraneDesflurane may increase the QTc-prolonging activities of Panobinostat.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Panobinostat.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Panobinostat.Approved
DeutetrabenazineThe serum concentration of Deutetrabenazine can be increased when it is combined with Panobinostat.Approved, Investigational
Dexchlorpheniramine maleateThe serum concentration of Dexchlorpheniramine maleate can be increased when it is combined with Panobinostat.Approved
DexfenfluramineThe serum concentration of Dexfenfluramine can be increased when it is combined with Panobinostat.Approved, Illicit, Investigational, Withdrawn
DexmethylphenidateThe serum concentration of Dexmethylphenidate can be increased when it is combined with Panobinostat.Approved
DextroamphetamineThe serum concentration of Dextroamphetamine can be increased when it is combined with Panobinostat.Approved, Illicit
DextromethorphanThe serum concentration of Dextromethorphan can be increased when it is combined with Panobinostat.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Panobinostat.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Panobinostat.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Panobinostat.Approved
DihydrocodeineThe serum concentration of Dihydrocodeine can be increased when it is combined with Panobinostat.Approved, Illicit
DihydroergotamineThe metabolism of Panobinostat can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Panobinostat.Approved
DiphenhydramineThe serum concentration of Diphenhydramine can be increased when it is combined with Panobinostat.Approved
DisopyramidePanobinostat may increase the QTc-prolonging activities of Disopyramide.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Panobinostat.Approved, Investigational
DofetilidePanobinostat may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronDolasetron may increase the arrhythmogenic activities of Panobinostat.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Panobinostat.Approved, Investigational, Vet Approved
DonepezilThe serum concentration of Donepezil can be increased when it is combined with Panobinostat.Approved
DopamineThe serum concentration of Dopamine can be increased when it is combined with Panobinostat.Approved
DoxazosinThe serum concentration of Doxazosin can be increased when it is combined with Panobinostat.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Panobinostat.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Panobinostat.Approved, Investigational
DoxycyclineThe metabolism of Panobinostat can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe serum concentration of Dronedarone can be increased when it is combined with Panobinostat.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Panobinostat.Approved, Vet Approved
DuloxetineThe serum concentration of Duloxetine can be increased when it is combined with Panobinostat.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Panobinostat.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Panobinostat.Approved
EnasidenibThe serum concentration of Enasidenib can be increased when it is combined with Panobinostat.Approved
EncainideThe serum concentration of Encainide can be increased when it is combined with Panobinostat.Approved, Investigational, Withdrawn
EnclomipheneThe serum concentration of Enclomiphene can be increased when it is combined with Panobinostat.Investigational
EnzalutamideThe serum concentration of Panobinostat can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Panobinostat.Approved, Investigational
EribulinEribulin may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Panobinostat.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Panobinostat.Approved, Vet Approved
EscitalopramThe serum concentration of Escitalopram can be increased when it is combined with Panobinostat.Approved, Investigational
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Panobinostat.Investigational
EthylmorphineThe serum concentration of Ethylmorphine can be increased when it is combined with Panobinostat.Approved, Illicit
EtoricoxibThe serum concentration of Etoricoxib can be increased when it is combined with Panobinostat.Approved, Investigational
EzogabineEzogabine may increase the QTc-prolonging activities of Panobinostat.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Panobinostat.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Panobinostat.Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Panobinostat.Approved
FingolimodPanobinostat may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FlecainideThe serum concentration of Flecainide can be increased when it is combined with Panobinostat.Approved, Withdrawn
FluconazoleFluconazole may increase the QTc-prolonging activities of Panobinostat.Approved
FlunarizineThe serum concentration of Flunarizine can be increased when it is combined with Panobinostat.Approved
FluoxetineThe serum concentration of Fluoxetine can be increased when it is combined with Panobinostat.Approved, Vet Approved
FlupentixolPanobinostat may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Fluphenazine can be increased when it is combined with Panobinostat.Approved
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Panobinostat.Approved
FluvoxamineThe serum concentration of Fluvoxamine can be increased when it is combined with Panobinostat.Approved, Investigational
FormoterolThe serum concentration of Formoterol can be increased when it is combined with Panobinostat.Approved, Investigational
FosamprenavirThe metabolism of Panobinostat can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Panobinostat can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Panobinostat.Approved
FosphenytoinThe serum concentration of Panobinostat can be decreased when it is combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Panobinostat can be increased when it is combined with Fusidic Acid.Approved
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Panobinostat.Investigational
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Panobinostat.Approved
GalantamineThe serum concentration of Galantamine can be increased when it is combined with Panobinostat.Approved
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Panobinostat.Approved, Investigational
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Panobinostat.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Panobinostat.Experimental
GoserelinGoserelin may increase the QTc-prolonging activities of Panobinostat.Approved
GranisetronGranisetron may increase the arrhythmogenic activities of Panobinostat.Approved, Investigational
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Panobinostat.Approved
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Panobinostat.Approved
HalothaneThe serum concentration of Halothane can be increased when it is combined with Panobinostat.Approved, Vet Approved
Hepatitis A VaccineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Panobinostat.Approved
Hepatitis B Vaccine (Recombinant)The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Panobinostat.Approved, Withdrawn
HistrelinHistrelin may increase the QTc-prolonging activities of Panobinostat.Approved
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Panobinostat.Approved, Illicit
HydromorphoneThe serum concentration of Hydromorphone can be increased when it is combined with Panobinostat.Approved, Illicit
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Panobinostat.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Panobinostat.Approved
IbutilidePanobinostat may increase the QTc-prolonging activities of Ibutilide.Approved
IdarubicinThe serum concentration of Idarubicin can be increased when it is combined with Panobinostat.Approved
IdelalisibThe serum concentration of Panobinostat can be increased when it is combined with Idelalisib.Approved
IloperidoneThe serum concentration of Iloperidone can be increased when it is combined with Panobinostat.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Panobinostat.Approved
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Panobinostat.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Panobinostat.Approved
IndapamideIndapamide may increase the QTc-prolonging activities of Panobinostat.Approved
IndinavirThe serum concentration of Panobinostat can be increased when it is combined with Indinavir.Approved
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Panobinostat.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Panobinostat.Investigational
Ipratropium bromideThe serum concentration of Ipratropium bromide can be increased when it is combined with Panobinostat.Approved
IsavuconazoniumThe metabolism of Panobinostat can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneIsoflurane may increase the QTc-prolonging activities of Panobinostat.Approved, Vet Approved
IsradipineIsradipine may increase the QTc-prolonging activities of Panobinostat.Approved
ItraconazoleThe serum concentration of Panobinostat can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Panobinostat.Approved
IvacaftorThe serum concentration of Panobinostat can be increased when it is combined with Ivacaftor.Approved
IxazomibThe serum concentration of Ixazomib can be increased when it is combined with Panobinostat.Approved
KetoconazoleThe serum concentration of Panobinostat can be increased when it is combined with Ketoconazole.Approved, Investigational
LabetalolThe serum concentration of Labetalol can be increased when it is combined with Panobinostat.Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Panobinostat.Experimental
LapatinibLapatinib may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Panobinostat is combined with Leflunomide.Approved, Investigational
LenvatinibPanobinostat may increase the QTc-prolonging activities of Lenvatinib.Approved
LetermovirThe serum concentration of Letermovir can be increased when it is combined with Panobinostat.Approved
LeuprolideLeuprolide may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
LevodopaThe serum concentration of Levodopa can be increased when it is combined with Panobinostat.Approved
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Panobinostat.Approved
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Panobinostat.Approved, Vet Approved
LisurideThe serum concentration of Lisuride can be increased when it is combined with Panobinostat.Approved, Investigational
LithiumLithium may increase the QTc-prolonging activities of Panobinostat.Approved
LomustineThe serum concentration of Lomustine can be increased when it is combined with Panobinostat.Approved
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Panobinostat.Approved
LopinavirThe serum concentration of Panobinostat can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Loratadine can be increased when it is combined with Panobinostat.Approved
LorcaserinThe serum concentration of Lorcaserin can be increased when it is combined with Panobinostat.Approved
LovastatinThe metabolism of Panobinostat can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Panobinostat can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Panobinostat can be decreased when it is combined with Lumacaftor.Approved
LumefantrinePanobinostat may increase the QTc-prolonging activities of Lumefantrine.Approved
MaprotilineThe serum concentration of Maprotiline can be increased when it is combined with Panobinostat.Approved
MefloquineMefloquine may increase the QTc-prolonging activities of Panobinostat.Approved
MephenytoinThe serum concentration of Mephenytoin can be increased when it is combined with Panobinostat.Investigational, Withdrawn
MequitazineThe serum concentration of Mequitazine can be increased when it is combined with Panobinostat.Approved
MesoridazineThe serum concentration of Mesoridazine can be increased when it is combined with Panobinostat.Approved, Investigational
MethadoneThe serum concentration of Methadone can be increased when it is combined with Panobinostat.Approved
MethamphetamineThe serum concentration of Methamphetamine can be increased when it is combined with Panobinostat.Approved, Illicit
MethotrimeprazineThe serum concentration of Methotrimeprazine can be increased when it is combined with Panobinostat.Approved
MethoxyfluraneThe serum concentration of Methoxyflurane can be increased when it is combined with Panobinostat.Approved, Investigational, Vet Approved
MethylphenidateThe serum concentration of Methylphenidate can be increased when it is combined with Panobinostat.Approved, Investigational
MethyprylonThe serum concentration of Methyprylon can be increased when it is combined with Panobinostat.Approved, Illicit, Withdrawn
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Panobinostat.Experimental
MetoclopramideThe serum concentration of Metoclopramide can be increased when it is combined with Panobinostat.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Panobinostat.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Panobinostat.Approved
MexiletineThe serum concentration of Mexiletine can be increased when it is combined with Panobinostat.Approved
MianserinThe serum concentration of Mianserin can be increased when it is combined with Panobinostat.Approved, Investigational
MifepristoneThe serum concentration of Panobinostat can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineThe serum concentration of Minaprine can be increased when it is combined with Panobinostat.Approved
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Panobinostat.Approved
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Panobinostat.Approved
MitotaneThe serum concentration of Panobinostat can be decreased when it is combined with Mitotane.Approved
MoclobemideThe serum concentration of Moclobemide can be increased when it is combined with Panobinostat.Approved
MoexiprilMoexipril may increase the QTc-prolonging activities of Panobinostat.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Panobinostat.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
NatalizumabThe risk or severity of adverse effects can be increased when Panobinostat is combined with Natalizumab.Approved, Investigational
NateglinideThe serum concentration of Nateglinide can be increased when it is combined with Panobinostat.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Panobinostat.Approved, Investigational
NefazodoneThe serum concentration of Panobinostat can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Panobinostat can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Netupitant can be increased when it is combined with Panobinostat.Approved
NevirapineThe serum concentration of Nevirapine can be increased when it is combined with Panobinostat.Approved
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Panobinostat.Approved
NicergolineThe serum concentration of Nicergoline can be increased when it is combined with Panobinostat.Approved, Investigational
NicotineThe serum concentration of Nicotine can be increased when it is combined with Panobinostat.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Panobinostat.Approved
NilotinibThe metabolism of Panobinostat can be decreased when combined with Nilotinib.Approved, Investigational
NitrofuralThe serum concentration of Nitrofural can be increased when it is combined with Panobinostat.Approved, Investigational, Vet Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Panobinostat.Approved
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Panobinostat.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Panobinostat.Approved
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Panobinostat.Approved, Investigational
OlaparibThe metabolism of Panobinostat can be decreased when combined with Olaparib.Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Panobinostat.Experimental, Investigational
OlodaterolOlodaterol may increase the QTc-prolonging activities of Panobinostat.Approved
OndansetronOndansetron may increase the arrhythmogenic activities of Panobinostat.Approved
OsimertinibThe serum concentration of Panobinostat can be increased when it is combined with Osimertinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Panobinostat.Approved
OxycodoneThe serum concentration of Oxycodone can be increased when it is combined with Panobinostat.Approved, Illicit, Investigational
OxymorphoneThe serum concentration of Oxymorphone can be increased when it is combined with Panobinostat.Approved, Investigational, Vet Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Panobinostat.Approved, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Panobinostat.Approved, Vet Approved
PalbociclibThe serum concentration of Panobinostat can be increased when it is combined with Palbociclib.Approved
PaliperidonePanobinostat may increase the QTc-prolonging activities of Paliperidone.Approved
PalonosetronThe serum concentration of Palonosetron can be increased when it is combined with Panobinostat.Approved, Investigational
ParoxetineThe serum concentration of Paroxetine can be increased when it is combined with Panobinostat.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Panobinostat.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Panobinostat.Approved
PentamidineThe serum concentration of Pentamidine can be increased when it is combined with Panobinostat.Approved
PentobarbitalThe serum concentration of Panobinostat can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PerflutrenPerflutren may increase the QTc-prolonging activities of Panobinostat.Approved
PerhexilineThe serum concentration of Perhexiline can be increased when it is combined with Panobinostat.Approved, Investigational
PerospironeThe serum concentration of Perospirone can be increased when it is combined with Panobinostat.Approved
PerphenazineThe serum concentration of Perphenazine can be increased when it is combined with Panobinostat.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Panobinostat.Experimental
PethidineThe serum concentration of Pethidine can be increased when it is combined with Panobinostat.Approved
PhenacetinThe serum concentration of Phenacetin can be increased when it is combined with Panobinostat.Withdrawn
PhenforminThe serum concentration of Phenformin can be increased when it is combined with Panobinostat.Approved, Investigational, Withdrawn
PhenobarbitalThe serum concentration of Panobinostat can be decreased when it is combined with Phenobarbital.Approved
PhenytoinThe serum concentration of Panobinostat can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Panobinostat.Approved, Investigational
PimozidePanobinostat may increase the QTc-prolonging activities of Pimozide.Approved
PindololThe serum concentration of Pindolol can be increased when it is combined with Panobinostat.Approved
PiperazineThe serum concentration of Piperazine can be increased when it is combined with Panobinostat.Approved, Vet Approved
PipotiazineThe serum concentration of Pipotiazine can be increased when it is combined with Panobinostat.Approved, Investigational
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Panobinostat.Approved
PosaconazoleThe serum concentration of Panobinostat can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PrimaquinePrimaquine may increase the QTc-prolonging activities of Panobinostat.Approved
PrimidoneThe serum concentration of Panobinostat can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcainamideThe serum concentration of Procainamide can be increased when it is combined with Panobinostat.Approved
ProchlorperazineThe serum concentration of Prochlorperazine can be increased when it is combined with Panobinostat.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Panobinostat.Approved, Vet Approved
PromazinePromazine may increase the QTc-prolonging activities of Panobinostat.Approved, Vet Approved
PromethazineThe serum concentration of Promethazine can be increased when it is combined with Panobinostat.Approved
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Panobinostat.Approved
PropofolThe serum concentration of Propofol can be increased when it is combined with Panobinostat.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Panobinostat.Approved, Investigational
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Panobinostat.Experimental
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Panobinostat.Approved
PseudoephedrineThe serum concentration of Pseudoephedrine can be increased when it is combined with Panobinostat.Approved
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Panobinostat.Approved
QuinidinePanobinostat may increase the QTc-prolonging activities of Quinidine.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Panobinostat.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Panobinostat is combined with Rabies virus inactivated antigen, A.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Panobinostat.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Panobinostat.Approved
RanolazineThe serum concentration of Panobinostat can be increased when it is combined with Ranolazine.Approved, Investigational
RemoxiprideThe serum concentration of Remoxipride can be increased when it is combined with Panobinostat.Approved, Withdrawn
repinotanThe serum concentration of repinotan can be increased when it is combined with Panobinostat.Investigational
RifabutinThe serum concentration of Panobinostat can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Panobinostat can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Panobinostat can be decreased when it is combined with Rifapentine.Approved
RilpivirineRilpivirine may increase the QTc-prolonging activities of Panobinostat.Approved
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Panobinostat.Investigational
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Panobinostat.Approved, Investigational
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Panobinostat.Approved, Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Panobinostat.Approved
RopivacaineThe serum concentration of Ropivacaine can be increased when it is combined with Panobinostat.Approved
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Panobinostat.Approved
RotigotineThe serum concentration of Rotigotine can be increased when it is combined with Panobinostat.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Panobinostat.Approved
RucaparibThe serum concentration of Rucaparib can be increased when it is combined with Panobinostat.Approved, Investigational
RupatadineThe serum concentration of Rupatadine can be increased when it is combined with Panobinostat.Approved
SalbutamolSalbutamol may increase the QTc-prolonging activities of Panobinostat.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Panobinostat.Approved
Salmonella typhi ty21a live antigenThe therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Panobinostat.Approved
SaquinavirThe serum concentration of Panobinostat can be increased when it is combined with Saquinavir.Approved, Investigational
SertindoleThe serum concentration of Sertindole can be increased when it is combined with Panobinostat.Approved, Investigational, Withdrawn
SertralineThe serum concentration of Sertraline can be increased when it is combined with Panobinostat.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Panobinostat.Approved, Vet Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Panobinostat.Approved, Investigational
SiltuximabThe serum concentration of Panobinostat can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Panobinostat can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Panobinostat.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Panobinostat.Approved
SolifenacinSolifenacin may increase the QTc-prolonging activities of Panobinostat.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
SotalolPanobinostat may increase the QTc-prolonging activities of Sotalol.Approved
SparteineThe serum concentration of Sparteine can be increased when it is combined with Panobinostat.Experimental
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Panobinostat.Investigational
St. John's WortThe serum concentration of Panobinostat can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Panobinostat can be increased when it is combined with Stiripentol.Approved
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Panobinostat.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Panobinostat.Approved, Vet Approved
SunitinibSunitinib may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Panobinostat.Approved, Investigational
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Panobinostat resulting in a loss in efficacy.Approved
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Panobinostat.Approved, Investigational
TapentadolThe serum concentration of Tapentadol can be increased when it is combined with Panobinostat.Approved
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Panobinostat.Investigational
TegaserodThe serum concentration of Tegaserod can be increased when it is combined with Panobinostat.Investigational, Withdrawn
TelaprevirThe serum concentration of Panobinostat can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelavancinTelavancin may increase the QTc-prolonging activities of Panobinostat.Approved
TelithromycinThe serum concentration of Panobinostat can be increased when it is combined with Telithromycin.Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Panobinostat.Approved
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Panobinostat.Withdrawn
TesmilifeneThe serum concentration of Tesmilifene can be increased when it is combined with Panobinostat.Investigational
TetrabenazineThe serum concentration of Tetrabenazine can be increased when it is combined with Panobinostat.Approved
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Panobinostat.Investigational
TheophyllineThe serum concentration of Theophylline can be increased when it is combined with Panobinostat.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Panobinostat.Approved, Withdrawn
ThiothixeneThiothixene may increase the QTc-prolonging activities of Panobinostat.Approved
TiclopidineThe serum concentration of Ticlopidine can be increased when it is combined with Panobinostat.Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Panobinostat.Approved
TiotropiumThe serum concentration of Tiotropium can be increased when it is combined with Panobinostat.Approved
TipranavirThe serum concentration of Tipranavir can be increased when it is combined with Panobinostat.Approved, Investigational
TizanidineTizanidine may increase the QTc-prolonging activities of Panobinostat.Approved
TocilizumabThe serum concentration of Panobinostat can be decreased when it is combined with Tocilizumab.Approved
TofacitinibPanobinostat may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolterodineThe serum concentration of Tolterodine can be increased when it is combined with Panobinostat.Approved, Investigational
ToremifenePanobinostat may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Panobinostat.Approved, Investigational
TramadolThe serum concentration of Tramadol can be increased when it is combined with Panobinostat.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Panobinostat.Approved, Investigational
TrazodoneThe serum concentration of Trazodone can be increased when it is combined with Panobinostat.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Panobinostat.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Panobinostat.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Panobinostat.Approved, Vet Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Panobinostat.Approved
ValbenazineThe serum concentration of Valbenazine can be increased when it is combined with Panobinostat.Approved, Investigational
VandetanibPanobinostat may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Panobinostat.Approved
Varicella Zoster Vaccine (Live/Attenuated)The therapeutic efficacy of Zoster vaccine can be decreased when used in combination with Panobinostat.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Panobinostat.Approved
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Panobinostat.Approved
VerapamilThe metabolism of Panobinostat can be decreased when combined with Verapamil.Approved
VernakalantThe serum concentration of Vernakalant can be increased when it is combined with Panobinostat.Approved, Investigational
VilanterolVilanterol may increase the QTc-prolonging activities of Panobinostat.Approved
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Panobinostat.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Panobinostat.Approved
VinorelbineThe serum concentration of Vinorelbine can be increased when it is combined with Panobinostat.Approved, Investigational
VoriconazoleThe serum concentration of Panobinostat can be increased when it is combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
VortioxetineThe serum concentration of Vortioxetine can be increased when it is combined with Panobinostat.Approved
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Panobinostat.Approved
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Panobinostat.Approved, Vet Approved
ZalcitabineThe serum concentration of Zalcitabine can be increased when it is combined with Panobinostat.Approved, Investigational
ZiprasidoneThe metabolism of Panobinostat can be decreased when combined with Ziprasidone.Approved
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Panobinostat.Approved
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Panobinostat.Approved, Investigational
Food Interactions
No interactions found.

References

General References
  1. Qian DZ, Kato Y, Shabbeer S, Wei Y, Verheul HM, Salumbides B, Sanni T, Atadja P, Pili R: Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin Cancer Res. 2006 Jan 15;12(2):634-42. [PubMed:16428510]
  2. Laubach JP, Moreau P, San-Miguel JF, Richardson PG: Panobinostat for the Treatment of Multiple Myeloma. Clin Cancer Res. 2015 Nov 1;21(21):4767-73. doi: 10.1158/1078-0432.CCR-15-0530. Epub 2015 Sep 11. [PubMed:26362997]
  3. Link [Link]
  4. Drugs of the Future - Panobinostat [Link]
External Links
KEGG Drug
D10019
PubChem Compound
6918837
PubChem Substance
310264874
ChemSpider
5294028
BindingDB
29589
ChEBI
85990
ChEMBL
CHEMBL483254
PharmGKB
PA166161307
HET
LBH
Drugs.com
Drugs.com Drug Page
Wikipedia
Panobinostat
ATC Codes
L01XX42 — Panobinostat
PDB Entries
5ef8
FDA label
Download (772 KB)
MSDS
Download (227 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0WithdrawnBasic ScienceCancer, Breast1
1Active Not RecruitingOtherNasopharyngeal Carcinoma, Lymphomas, Any EBV+ Solid Tumour1
1Active Not RecruitingTreatmentAdvanced Myelodysplastic Syndrome / Leukemia Acute Myeloid Leukemia (AML)1
1Active Not RecruitingTreatmentChronic Myelomonocytic Leukemia / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes1
1Active Not RecruitingTreatmentIdiopathic Myelofibrosis / Post Essential Thrombocythemia Myelofibrosis / Post Polycythemia-Vera Myelofibrosis1
1Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Tumors, Solid1
1Active Not RecruitingTreatmentMelanoma / Skin Cancers1
1Active Not RecruitingTreatmentMultiple Myeloma (MM)2
1Active Not RecruitingTreatmentMultiple Myeloma in Relapse1
1Active Not RecruitingTreatmentPlasma Cell Myeloma2
1CompletedNot AvailableAdvanced Solid Tumors2
1CompletedTreatmentAdvanced Solid Tumors1
1CompletedTreatmentAdvanced Solid Tumors / Cancers1
1CompletedTreatmentCancer Patients With Advanced Solid Tumors Including Lymphoma or Chronic Hematological Malignancies1
1CompletedTreatmentCancer, Breast1
1CompletedTreatmentCancers1
1CompletedTreatmentChronic Myelomonocytic Leukemia (CMML) / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes (MDS)1
1CompletedTreatmentCutaneous T-Cell Lymphoma (CTCL) / Tumors1
1CompletedTreatmentEsophageal Cancers / Head & Neck Cancer / Prostate Cancer1
1CompletedTreatmentHER-2 Positive Breast Cancer / Metastatic Breast Cancer (MBC)1
1CompletedTreatmentHead and Neck Carcinoma / Lung Cancers1
1CompletedTreatmentHodgkins Disease (HD) / Lymphoblastic Leukemia, Acute, Childhood / Myelogenous Leukemia, Acute, Childhood / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML)2
1CompletedTreatmentLeukemias1
1CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Mesothelioma1
1CompletedTreatmentMalignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm1
1CompletedTreatmentMalignant Melanoma / Melanoma1
1CompletedTreatmentMantle Cell Lymphoma (MCL)1
1CompletedTreatmentMultiple Myeloma (MM)1
1CompletedTreatmentNeoplasms / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentProstate Cancer1
1CompletedTreatmentTumors, Solid1
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1RecruitingTreatmentColorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer / Colorectal Cancers / Non-small Cell Lung Carcinoma (Adenocarcinoma) / Triple Negative Breast Cancer (TNBC)1
1RecruitingTreatmentDiffuse Intrinsic Pontine Glioma (DIPG)1
1RecruitingTreatmentGliomas1
1RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome1
1RecruitingTreatmentSickle Cell Disorders1
1TerminatedTreatmentBrain Metastasis / High-grade Meningioma / Recurrent Gliomas1
1TerminatedTreatmentHormone Refractory Prostate Cancer1
1TerminatedTreatmentHormone Refractory Prostate Cancer Disease1
1TerminatedTreatmentLiver Cancer1
1TerminatedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
1TerminatedTreatmentLymphoma, Hodgkins / Non-Hodgkin's Lymphoma (NHL)1
1TerminatedTreatmentMultiple Myeloma (MM)1
1TerminatedTreatmentRecurrent Colon Cancer / Recurrent Rectal Cancer / Stage IV Colon Cancer / Stage IV Rectal Cancer1
1TerminatedTreatmentTumors, Solid1
1Unknown StatusTreatmentChordomas1
1Unknown StatusTreatmentHepatocellular,Carcinoma1
1Unknown StatusTreatmentLymphoma, Hodgkins1
1WithdrawnTreatmentLung Cancers1
1, 2Active Not RecruitingTreatmentAdult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / B-cell Adult Acute Lymphoblastic Leukemia / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Nodal marginal zone B-cell lymphomas / Post-Transplant Lymphoproliferative Disorder / Primary Central Nervous System Non-Hodgkin Lymphoma / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Multiple Myeloma / Splenic Marginal Zone Lymphoma / T-cell Adult Acute Lymphoblastic Leukemia / Waldenstrom's Macroglobulinemia (WM)1
1, 2Active Not RecruitingTreatmentAgnogenic Myeloid Metaplasia1
1, 2Active Not RecruitingTreatmentCancer, Breast1
1, 2Active Not RecruitingTreatmentKahler Disease / Multiple Myeloma (MM) / Myeloma, Plasma-Cell / Plasma Cell Myeloma1
1, 2Active Not RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome1
1, 2Active Not RecruitingTreatmentMultiple Myeloma (MM)2
1, 2CompletedTreatmentAcute Myeloblastic Leukemia1
1, 2CompletedTreatmentGraft Versus Host Disease (GVHD)1
1, 2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1, 2CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes1
1, 2CompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma (MM)1
1, 2CompletedTreatmentLymphoma, Hodgkins1
1, 2CompletedTreatmentMalignant Gliomas1
1, 2CompletedTreatmentMalignant Lymphomas1
1, 2CompletedTreatmentMetastatic Melanoma1
1, 2CompletedTreatmentMultiple Myeloma (MM)1
1, 2CompletedTreatmentProstate Cancer / Prostatic Neoplasms1
1, 2RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1, 2TerminatedTreatmentCancer, Breast1
1, 2TerminatedTreatmentCancer, Breast / Neoplasms, Breast / Tumors, Breast1
1, 2TerminatedTreatmentClear Cell Renal Cell Carcinoma / Recurrent Renal Cell Cancer / Stage III Renal Cell Cancer / Stage IV Renal Cell Cancer1
1, 2Unknown StatusTreatmentPolycythemia Vera, Post-Polycythemic Myelofibrosis Phase / Post-Essential Thrombocythemia Related Myelofibrosis / Primary Myelofibrosis1
1, 2WithdrawnTreatmentMultiple Myeloma (MM)1
2Active Not RecruitingBasic ScienceLymphoma in Leukemic Phase / Lymphoma With Cutaneous Involvement / Marrow Involvement With Lymphoma / Multiple Myeloma (MM) / Nodal Lymphoma1
2Active Not RecruitingTreatmentAdult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Nodal marginal zone B-cell lymphomas / Peripheral T-Cell Lymphoma (PTCL) / Post-Transplant Lymphoproliferative Disorder / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2Active Not RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)2
2Active Not RecruitingTreatmentNeoplasms, Hematologic1
2Active Not RecruitingTreatmentWaldenstrom's Macroglobulinemia (WM)1
2CompletedPreventionProstate Cancer1
2CompletedTreatmentAcute Myelogenous Leukaemia (AML) / Refractory Leukemia1
2CompletedTreatmentAdult Lymphocyte Depletion Hodgkin Lymphoma / Adult Lymphocyte Predominant Hodgkin Lymphoma / Adult Mixed Cellularity Hodgkin Lymphoma / Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma / Adult Nodular Sclerosis Hodgkin Lymphoma / Recurrent Adult Hodgkin's Lymphoma1
2CompletedTreatmentAnaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative) / Angioimmunoblastic T-Cell Lymphoma / Enteropathy- Type T-cell Lymphoma / Extranodal NK/T-cell Lymphoma Nasal Type / Hepatosplenic T-Cell Lymphoma / Peripheral T-cell Lymphoma (Not Otherwise Specified) / Relapsed ALCL (ALK-1 Positive) Post Autologous Transplant1
2CompletedTreatmentCancer, Breast1
2CompletedTreatmentClassical Hodgkin's Lymphoma (i.e. Nodular Sclerosing, Mixed-cellularity, Lymphocyte-rich, Lymphocyte-depleted)1
2CompletedTreatmentColorectal Cancers1
2CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2CompletedTreatmentMultiple Myeloma (MM)1
2CompletedTreatmentNeuroendocrine Tumors1
2CompletedTreatmentPost-Essential Thrombocytopenia / Post-Polycythaemia Vera / Primary Myelofibrosis1
2CompletedTreatmentRenal Cell Adenocarcinoma1
2CompletedTreatmentSmall Cell Lung Carcinoma1
2CompletedTreatmentSoft Tissue Sarcoma (STS)1
2CompletedTreatmentThyroid Carcinoma1
2Not Yet RecruitingTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
2RecruitingPreventionGraft Versus Host Disease (GVHD)1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemia, B-Cell / Leukemia, T-Cell / Non-Hodgkin's Lymphoma (NHL)1
2RecruitingTreatmentMultiple Myeloma (MM)4
2RecruitingTreatmentRelapse/Refractory Multiple Myeloma1
2TerminatedNot AvailableRecurrent Malignant Gliomas1
2TerminatedTreatmentAdult T-cell lymphomas/leukaemias / Cutaneous T-Cell Lymphoma (CTCL)1
2TerminatedTreatmentCancer, Breast1
2TerminatedTreatmentLeukemias1
2TerminatedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2TerminatedTreatmentMalignant Neoplasm of Pancreas1
2TerminatedTreatmentMetastatic Gastric Cancers1
2TerminatedTreatmentMultiple Myeloma (MM)1
2TerminatedTreatmentMyelodysplastic Syndrome1
2TerminatedTreatmentMyelodysplastic Syndromes (MDS)2
2TerminatedTreatmentNon-Hodgkin's Lymphoma (NHL)1
2WithdrawnTreatmentChronic Graft Versus Host Disease1
2WithdrawnTreatmentMalignant Lymphomas1
2WithdrawnTreatmentMultiple Myeloma (MM)1
2WithdrawnTreatmentRecurrent Glioblastoma1
2, 3CompletedTreatmentChronic Myeloid Leukemia in Chronic Phase1
2, 3CompletedTreatmentCutaneous T-Cell Lymphoma (CTCL)2
2, 3CompletedTreatmentLeukemia,Myeloid, Chronic1
3CompletedTreatmentLymphoma, Hodgkins1
3CompletedTreatmentMultiple Myeloma (MM)1
4CompletedTreatmentMultiple Myeloma in Relapse / Refractory Multiple Myeloma / Relapsed and Bortezomib Refractory Multiple Myeloma1
Not AvailableAvailableNot AvailableMultiple Myeloma (MM)1
Not AvailableNo Longer AvailableNot AvailableMultiple Myeloma (MM)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
CapsuleOral10 mg
CapsuleOral10 mg/1
CapsuleOral15 mg
CapsuleOral15 mg/1
CapsuleOral20 mg/1
CapsuleOral20 mg
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7067551No2001-08-312021-08-31Us
US6833384No2001-09-302021-09-30Us
US8883842No2008-06-132028-06-13Us
US6552065No2001-08-312021-08-31Us
US7989494No2008-01-172028-01-17Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000834 mg/mLALOGPS
logP3.28ALOGPS
logP1.54ChemAxon
logS-5.6ALOGPS
pKa (Strongest Acidic)5.45ChemAxon
pKa (Strongest Basic)10.01ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area80.64 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity106.02 m3·mol-1ChemAxon
Polarizability40.54 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as tryptamines and derivatives. These are compounds containing the tryptamine backbone, which is structurally characterized by an indole ring substituted at the 3-position by an ethanamine.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Indoles and derivatives
Sub Class
Tryptamines and derivatives
Direct Parent
Tryptamines and derivatives
Alternative Parents
Cinnamic acids and derivatives / 3-alkylindoles / Styrenes / Phenylmethylamines / Benzylamines / Aralkylamines / Substituted pyrroles / Heteroaromatic compounds / Hydroxamic acids / Amino acids and derivatives
show 6 more
Substituents
Cinnamic acid or derivatives / Tryptamine / 3-alkylindole / Indole / Benzylamine / Phenylmethylamine / Styrene / Aralkylamine / Benzenoid / Substituted pyrrole
show 19 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
secondary amino compound, hydroxamic acid, cinnamamides, methylindole (CHEBI:85990)

Targets

Kind
Protein group
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Transcription regulatory region sequence-specific dna binding
Specific Function
Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an impo...

Components:
References
  1. Beckers T, Burkhardt C, Wieland H, Gimmnich P, Ciossek T, Maier T, Sanders K: Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. Int J Cancer. 2007 Sep 1;121(5):1138-48. [PubMed:17455259]
  2. Geng L, Cuneo KC, Fu A, Tu T, Atadja PW, Hallahan DE: Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer. Cancer Res. 2006 Dec 1;66(23):11298-304. [PubMed:17145876]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Richardson PG, Harvey RD, Laubach JP, Moreau P, Lonial S, San-Miguel JF: Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes. Expert Rev Clin Pharmacol. 2016;9(1):35-48. doi: 10.1586/17512433.2016.1096773. Epub 2015 Oct 26. [PubMed:26503877]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Richardson PG, Harvey RD, Laubach JP, Moreau P, Lonial S, San-Miguel JF: Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes. Expert Rev Clin Pharmacol. 2016;9(1):35-48. doi: 10.1586/17512433.2016.1096773. Epub 2015 Oct 26. [PubMed:26503877]
  2. Bailey H, Stenehjem DD, Sharma S: Panobinostat for the treatment of multiple myeloma: the evidence to date. J Blood Med. 2015 Oct 8;6:269-76. doi: 10.2147/JBM.S69140. eCollection 2015. [PubMed:26504410]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Bailey H, Stenehjem DD, Sharma S: Panobinostat for the treatment of multiple myeloma: the evidence to date. J Blood Med. 2015 Oct 8;6:269-76. doi: 10.2147/JBM.S69140. eCollection 2015. [PubMed:26504410]

Drug created on March 19, 2008 10:40 / Updated on December 01, 2017 17:29